The "Elevate" by MAPS Podcast

In this second of two podcasts, Pete Piliero, MD, VP & Head, Medical Affairs Americas, GSK Consumer Healthcare, moderates a discussion on Global/Regional/Local Planning; Approach to MA Strategic Planning - Rare Disease & Oncology; and, Compliance Considerations.Panelists are: Tina Beaman, VP and Chief Compliance Officer, Karyopharm Therapeutics Ed Gudaitis, President & CEO Acerus Pharma Keith Johns, VP, Global Marketing and Alliance Management, Eli Lilly & Co Maria Rivas, Chief Medical Officer, EMD Serono/Merck KGaA

In this first of two podcasts, Pete Piliero, MD, VP & Head, Medical Affairs Americas, GSK Consumer Healthcare, moderates a discussion on Contributions Medical Affairs Makes to Asset Strategic Plans; and Time Horizon, Refreshing, and Resourcing of a Medical Affairs Plan. Panelists are: Ed Gudaitis, MBA, President & CEO Acerus Pharma Keith Johns, MBA, VP, Global Marketing and Alliance Management, Eli Lilly & Co; Maria Rivas, MD, Chief Medical Officer, EMD Serono/Merck KGaA 

Cerise James, MD, moderates this podcast presentation by the MAPS Evidence Generation Focus Area Working Group in which Neil Belson, JD, discusses Real World Evidence and its impact. The podcast objectives are: To define Real World Evidence, and to demonstrate RWE and its impact to Biotech/Pharma.Mr. Belson will address a variety of topics including: The significance of Real World Evidence for the pharmaceutical and medical device industry; and, how the FDA views Real World Evidence. This is the first podcast in a series.

In this second podcast on the EUMDR, panelists John Pracyk, MD, PhD, MBA, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, DePuy Synthes - Spine | Johnson & Johnson Medical Devices Companies welcomes Philip Desjardins, JD, Vice President, Global Regulatory Affairs Spine and Medical Device Regulatory Policy, DePuy Synthes | Johnson & Johnson Medical Devices Companies, and Drilon Saliu, PharmD, MBA, Head, Medical, Clinical and HEOR, Connected Care, Philips, continue their comprehensive discussion of: Covid’s impact on EUMDR; USFDA and EUMDR global regulator comparison; short and long term impacts; how Brexit might impact the UK’s regulatory oversight; the importance of investing in top talent; new capabilities that are required; the importance of leading with influence; and, evidentiary compliance planning and budget impact.

Host John Pracyk, MD, PhD, MBA, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, DePuy Synthes - Spine | Johnson & Johnson Medical Devices Companies welcomes Philip Desjardins, JD, Vice President, Global Regulatory Affairs Spine and Medical Device Regulatory Policy, DePuy Synthes | Johnson & Johnson Medical Devices Companies, and Drilon Saliu, PharmD, MBA, Head, Medical, Clinical and HEOR, Connected Care, Philips, to share insights into the importance of compliance with the new European Device Medical Regulation (EUMDR), including key deadlines for compliance. 

Hosts John Pracyk, MD, PhD, MBA, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, Depuy Synthes - Spine | Johnson & Johnson Medical Devices Companies and Marc Rubinstein, MD, Medical Director at Instrumentation Laboratory, welcome panelists Huub Kreuwel PhD, Vice President of Scientific and Medical Affairs at Octapharma, and Sean Lilienfeld MBBCh, MMEd(Neuro), FCP (Neuro), FAAN, a neurologist by training, and currently Vice President of Global Medical Affairs Clinical Operations, Pre-Clinical Research, and Clinical Strategy at Boston Scientific, two professionals who have successfully transitioned careers between MedTech and Pharma, and reciprocally, Pharma and MedTech.

While there are similarities in decision making between Pharma and MedTech, it can be difficult to get face time with physicians but is still relatively easy to get face time with surgeons particularly when the medical technology is more complex. Asking what success looks like to the patient is a critical element in a successful career transition.

If you’re considering a career transition, asking: “What’s in it for me?” is just as important as “What’s in it for the company?” During this podcast, Dr. Rubinstein asks the panelists, Dr. Sean Lilienfeld and Huub Kreuwel, why they considered making the change from one area to another. The potential for expanding your skillsets is an important consideration but it is not the only one.

Do you possess the ability to empathize, but also the business acumen to understand your audience? MA professionals interact with a variety of stakeholders, so you must possess the skills necessary to be relatable and to present information in a meaningful way to a wide audience. 

Teams are traditionally smaller in MedTech than in Pharma. In MedTech companies, the MA professional may be asked to manage smaller teams and broader areas of responsibilities. This may be the case if you work for a smaller Pharma company, but larger Pharma companies may require more focused responsibilities.